Sepio Capital LP Sells 70,723 Shares of Pfizer Inc. (NYSE:PFE)

Sepio Capital LP cut its stake in Pfizer Inc. (NYSE:PFE) by 80.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 16,889 shares of the biopharmaceutical company’s stock after selling 70,723 shares during the period. Sepio Capital LP’s holdings in Pfizer were worth $486,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also modified their holdings of the stock. VisionPoint Advisory Group LLC lifted its holdings in Pfizer by 52,350.0% during the 3rd quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock worth $35,000 after buying an additional 1,047 shares in the last quarter. GoalVest Advisory LLC raised its position in shares of Pfizer by 304.9% during the fourth quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 811 shares during the last quarter. Tennessee Valley Asset Management Partners acquired a new position in shares of Pfizer during the fourth quarter valued at $36,000. DiNuzzo Private Wealth Inc. bought a new position in Pfizer in the fourth quarter valued at about $37,000. Finally, Life Planning Partners Inc bought a new stake in Pfizer during the 4th quarter worth about $39,000. 68.36% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on PFE shares. BMO Capital Markets reiterated an “outperform” rating and set a $36.00 price target (up previously from $33.00) on shares of Pfizer in a research report on Thursday, May 2nd. Guggenheim initiated coverage on Pfizer in a research note on Friday, February 23rd. They set a “buy” rating and a $36.00 price objective for the company. Argus lowered Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Morgan Stanley boosted their target price on Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a research report on Thursday, May 2nd. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a research report on Monday, April 15th. Ten research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Pfizer has an average rating of “Hold” and an average price target of $35.86.

Pfizer Stock Up 0.7 %

NYSE:PFE traded up $0.19 during trading hours on Friday, reaching $28.88. 22,589,127 shares of the stock were exchanged, compared to its average volume of 44,974,800. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.05 and a quick ratio of 0.78. Pfizer Inc. has a twelve month low of $25.20 and a twelve month high of $40.37. The stock has a market cap of $163.65 billion, a PE ratio of -481.25, a PEG ratio of 1.13 and a beta of 0.63. The firm has a 50 day moving average of $27.27 and a 200 day moving average of $27.94.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share for the quarter, beating the consensus estimate of $0.56 by $0.26. Pfizer had a positive return on equity of 8.64% and a negative net margin of 0.56%. The company had revenue of $14.88 billion during the quarter, compared to analysts’ expectations of $13.87 billion. During the same quarter last year, the company earned $1.23 EPS. Pfizer’s revenue for the quarter was down 19.5% compared to the same quarter last year. On average, equities analysts expect that Pfizer Inc. will post 2.38 earnings per share for the current year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, June 14th. Shareholders of record on Friday, May 10th will be given a dividend of $0.42 per share. This represents a $1.68 annualized dividend and a yield of 5.82%. The ex-dividend date is Thursday, May 9th. Pfizer’s dividend payout ratio (DPR) is currently -2,799.53%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.